Venture Capital

Immune Design Nets $18M in Series A

Immune Design is the latest company to try and ride the adaptive immune response wave.  Their approach is to create vaccines that: “use novel adjuvants and target dendritic cells.”  Well, that’s instructive.  The fledgling company has three employees and has just raised a hefty $18M in series A funding from Alta Partners, The Column Group and Versant.

I’m not sure what this means, exactly, but apparently all of the dozen or so rock star scientists associated with the company are excited. The press release reads like Dick Schapp book… 3 of the 7 paragraphs are just names of the famous scientists closely associated with the company. Name dropping doesn’t impress me.

The press release also indicates human trials within a year, so it seems that they have the petal to the floor. To me, it screams of quick exit by M&A, but of course, you never know. 

> Read the press release here (PR Newswire)

Theoretically Related Posts

• November 17, 2008 -- Pacira Pharmaceuticals Raises $85 Million in Series A (0)
• October 22, 2008 -- Apitope Raises EUR 10 Million in Series A Financing (0)
• August 25, 2008 -- Proteostasis Rakes in $45M in Series A (0)
• November 18, 2008 -- Numerate Completes $4 Million Series A (0)
• November 17, 2008 -- Zafgen Raises $14 Million in Series B (0)
• October 30, 2008 -- Alnara Pharmaceuticals, Inc. Secures $20 Million in Series A Round (0)
• October 22, 2008 -- Neuroptix Raises $18.5 Million in Successful B Round (0)
• October 16, 2008 -- Predictive Biosciences Closes $21.75 Million in Series B Financing (0)
• July 7, 2008 -- Secretive Agios Makes Splash with $33M Series A (0)
• June 11, 2008 -- Genentech and Symphogen Team Up For $330M (0)

© 2008 Pharmababble.